ArticleJournal of neurology2025
Relapses during treatment with monoclonal antibodies targeting B-cells in NMOSD.
Article in Journal of neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- CAR T cell therapy in autoantibody-mediated neurological disorders: a promising strategy.Journal of neuroinflammation · 2026Review
- Outcomes and predictors of relapse and severe pneumonia in Chinese patients with AQP4-IgG-positive neuromyelitis optica spectrum disorder receiving inebilizumab: a prospective cohort study.Frontiers in immunology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
introductionWhile sustained B-cell depletion has proven effective in maintaining a relapse-free state in patients with neuromyelitis optica spectrum disorder (NMOSD), B-cell-depleting therapies do not demonstrate efficacy in all cases. This study aims to investigate the risk factors associated with relapses during B-cell-targeting monoclonal antibody (mAb) treatment in patients with NMOSD.
methodsWe retrospectively analyzed baseline clinical characteristics, B-cell test results, and relapse data from NMOSD patients who received B-cell-targeting mAb treatment at four medical centers from July 2014 to September 2024. The annualized relapse rates (ARR) before and after mAb treatment were compared, and potential risk factors for relapses during mAb treatment were evaluated using a Cox proportional hazard model.
resultsThis study included 101 NMOSD patients, comprising 14 patients treated with inebilizumab (INEB) and 87 with rituximab (RTX). The patients' mean age at mAb initiation was 49 years (range: 10-74), with a median follow-up duration of 21.5 months (9.4, 37.6). During the study period, two patients were lost to follow-up, one died, and 17 experienced relapses, yielding a relapse-free rate of 83.2%. The ARR showed a significant reduction from 0.3 (0, 0.9) before mAb initiation to 0 (0, 0) after treatment (p = 0.002). Kaplan-Meier curve analysis demonstrated that patients with clustered attacks had a significantly higher risk of relapses compared to those without clustered attacks before mAb initiation (p < 0.001). Similarly, patients with EDSS scores ≥ 6 showed a higher relapse risk than those with EDSS scores < 6 (p = 0.006). Cox proportional hazard models identified several significant risk factors for relapses during mAb treatment, including the total number of attacks (including 2-year, 1-year, and clustered attacks), disease duration, ARR, and EDSS scores ≥ 6 before mAb initiation. Furthermore, patients who experienced relapses with CD19
conclusionAttack frequency and cumulative disability before mAb initiation are important predictors for relapses during targeted B-cell mAb treatment for NMOSD. Future therapeutic strategies should focus on preventing clustered attacks to reduce the likelihood of mAb treatment failure.
Indexed as
Identifiers
40383834What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.